Editas Medicine, Inc.: Form 10-Q for the period ended Mar 31, 2019
Filed with the SEC on May 8, 2019 and accepted by EDGAR at May 8, 2019, 16:03 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2019-01-01 to 2019-03-31 | $15.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-01-01 to 2019-03-31 | −$31.3m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2019-01-01 to 2019-03-31 | −$29.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-01-01 to 2019-03-31 | −$0.60 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 3 months2019-01-01 to 2019-03-31 | −$29.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2019-01-01 to 2019-03-31 | $718.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2019-03-31 | $157.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-03-31 | $347.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-03-31 | $378.9m | us-gaap:Assets |
| Current liabilities | At period end2019-03-31 | $41.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-03-31 | $161.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-03-31 | $217.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-19-004444. Last ingested by Listed: Nov 6, 2026, 17:42 ET. Listed shows no prices and gives no investment advice.